Details:
Under the agreement, Celltrion and LISCure intend to develop, oral LBPs, microbiome-based therapies, for Parkinson's disease. LISCure advances brain-target bacterial exosome technology for neurodegenerative diseases based on its platform technology.
Lead Product(s): Microbiome-based Therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Celltrion
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 20, 2023
Details:
Under the collaboration agreement, BIORCHESTRA, that develops RNA therapeutics for neurodegenerative diseases, will be responsible for target discovery, selection, and synthesis via its in-house technology by using antisense oligonucleotides.
Lead Product(s): Antisense Oligonucleotides
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: SK Biopharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 05, 2022